PREVIOUS
✖
HGCO19
April 17 , 2021
1318 days
898
0
- An additional government funding has been received by India’s mRNA-based Covid-19 vaccine candidate-HGCO19 for its clinical studies.
- This funding has been awarded under the ‘Mission Covid Suraksha’.
- It has been developed by Pune-based biotechnology company Gennova Biopharmaceuticals in collaboration with HDT Biotech Corporation, USA.
Leave a Reply
Your Comment is awaiting moderation.